Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) in China to proceed with a clinical study for its radiotherapeutic drug, 177Lu-LNC1004, which targets advanced solid tumors. The drug is designed to treat fibroblast activation protein (FAP)-positive advanced solid tumors, and there is currently no similar product approved globally.
177Lu-LNC1004 is a radiotherapeutic agent that homes in on FAP, a type II transmembrane serine protease that is highly expressed in many epithelial tumor-associated fibroblasts (CAFs), including those associated with gastric, esophageal, lung, colorectal, and ovarian cancers. Preclinical and clinical studies have demonstrated that 177Lu-LNC1004 can precisely and effectively target and kill solid tumor cells in gastric, esophageal, lung, and thyroid cancers, showing significant therapeutic efficacy.- Flcube.com
